James L. Gulley

27.7k total citations · 6 hit papers
568 papers, 18.4k citations indexed

About

James L. Gulley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, James L. Gulley has authored 568 papers receiving a total of 18.4k indexed citations (citations by other indexed papers that have themselves been cited), including 360 papers in Oncology, 255 papers in Pulmonary and Respiratory Medicine and 244 papers in Immunology. Recurrent topics in James L. Gulley's work include Cancer Immunotherapy and Biomarkers (261 papers), Immunotherapy and Immune Responses (220 papers) and Prostate Cancer Treatment and Research (199 papers). James L. Gulley is often cited by papers focused on Cancer Immunotherapy and Biomarkers (261 papers), Immunotherapy and Immune Responses (220 papers) and Prostate Cancer Treatment and Research (199 papers). James L. Gulley collaborates with scholars based in United States, Germany and France. James L. Gulley's co-authors include Jeffrey Schlom, Ravi A. Madan, Philip M. Arlen, William L. Dahut, Seth M. Steinberg, Christopher R. Heery, Caroline Jochéms, Kwong Y. Tsang, James W. Hodge and Renee N. Donahue and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

James L. Gulley

553 papers receiving 18.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 727 citations Jeffrey Schlom, William L. Dahut et al. profile →
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Alain Ravaud, James L. Gulley et al. profile →
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 429 citations Alain Ravaud, James L. Gulley et al. profile →
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 327 citations Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research profile →
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

2019 319 citations James L. Gulley et al. profile →
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

2024 64 citations James L. Gulley et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James L. Gulley United States	71	11.7k	8.3k	5.7k	4.2k	1.9k	568	18.4k
Sandra Demaria United States	65	14.7k 1.3×	10.6k 1.3×	4.8k 0.8×	3.6k 0.9×	2.9k 1.5×	192	21.7k
Mario Sznol United States	67	13.8k 1.2×	7.8k 0.9×	4.3k 0.8×	5.6k 1.3×	981 0.5×	270	19.8k
Daniel S. Chen United States	29	13.3k 1.1×	8.5k 1.0×	4.6k 0.8×	5.1k 1.2×	1.1k 0.6×	50	20.1k
Aurélien Marabelle France	63	10.2k 0.9×	5.8k 0.7×	3.1k 0.5×	2.8k 0.7×	1.7k 0.9×	281	15.2k
Omid Hamid United States	68	21.3k 1.8×	9.8k 1.2×	4.9k 0.9×	8.0k 1.9×	1.2k 0.6×	414	26.3k
Lawrence Fong United States	52	8.9k 0.8×	8.2k 1.0×	2.9k 0.5×	4.5k 1.1×	756 0.4×	268	16.2k
Patrick A. Ott United States	57	11.3k 1.0×	5.6k 0.7×	3.5k 0.6×	3.6k 0.9×	813 0.4×	240	15.6k
Christina B. Walter Germany	6	18.1k 1.6×	8.9k 1.1×	6.3k 1.1×	6.7k 1.6×	1.3k 0.7×	13	25.0k
Padmanee Sharma United States	63	20.0k 1.7×	13.9k 1.7×	5.8k 1.0×	6.5k 1.6×	1.2k 0.6×	257	28.5k
Michele Maio Italy	66	11.4k 1.0×	6.9k 0.8×	3.3k 0.6×	7.3k 1.8×	1.1k 0.6×	376	18.5k

Countries citing papers authored by James L. Gulley

Since Specialization

Citations

This map shows the geographic impact of James L. Gulley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James L. Gulley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James L. Gulley more than expected).

Fields of papers citing papers by James L. Gulley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James L. Gulley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James L. Gulley. The network helps show where James L. Gulley may publish in the future.

Co-authorship network of co-authors of James L. Gulley

This figure shows the co-authorship network connecting the top 25 collaborators of James L. Gulley. A scholar is included among the top collaborators of James L. Gulley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James L. Gulley. James L. Gulley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goswami, Meghali, Christine M. Minnar, Dara Bracken‐Clarke, et al.. (2025). Increased Peripheral T Stem Cell–like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy. Clinical Cancer Research. 31(19). 4159–4173. 1 indexed citations

Redman, Jason M., Renee N. Donahue, Jennifer L. Marté, et al.. (2025). Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection. The Oncologist. 30(3).

Strong, Jennifer, Margaret E. Gatti‐Mays, Julius Strauss, et al.. (2025). Case Report: The immune architecture of immunotherapy-induced cutaneous sarcoidosis resembles peritumoral inflammation. Frontiers in Immunology. 16. 1432927–1432927.

Okada, Reona, Taisuke Kondo, Jangsuk Oh, et al.. (2025). GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15/IL21 Exhibit Enhanced Activity against Neuroblastoma. Cancer Immunology Research. 13(9). 1363–1373. 1 indexed citations

Robbins, Yvette, Jay Friedman, Jason M. Redman, et al.. (2023). Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer. Oral Oncology. 138. 106309–106309. 6 indexed citations

Cho, Byoung Chul, Amaury Daste, Alain Ravaud, et al.. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Journal for ImmunoTherapy of Cancer. 8(2). e000664–e000664. 69 indexed citations

Bilušić, Marijo & James L. Gulley. (2020). Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. JNCI Journal of the National Cancer Institute. 113(7). 799–800. 8 indexed citations

Trostel, Shana Y., Olga Voznesensky, Rachel Schaefer, et al.. (2019). Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precision Oncology. 3(3). 1–13. 49 indexed citations

Strauss, Julius, Christopher R. Heery, Jeffrey Schlom, et al.. (2018). Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clinical Cancer Research. 24(6). 1287–1295. 327 indexed citations breakdown →

10.

Heery, Christopher R., Claudia Palena, Sheri McMahon, et al.. (2017). Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clinical Cancer Research. 23(22). 6833–6845. 51 indexed citations

11.

Lepone, Lauren M., Renee N. Donahue, Italia Grenga, et al.. (2016). Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. 5(1). 3 indexed citations

12.

Farsaci, Benedetto, Renee N. Donahue, Italia Grenga, et al.. (2016). Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research. 4(9). 755–765. 26 indexed citations

13.

Gulley, James L., et al.. (2013). Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. Clinical Cancer Research. 19(5). 1290–1299. 36 indexed citations

14.

Gulley, James L., Ravi A. Madan, Kwong Y. Tsang, et al.. (2013). Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. Cancer Immunology Research. 2(2). 133–141. 101 indexed citations

15.

Mohebtash, Mahsa, Kwong-Yok Tsang, Ravi A. Madan, et al.. (2011). A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. Clinical Cancer Research. 17(22). 7164–7173. 101 indexed citations

16.

Stein, Wilfred D., James L. Gulley, Jeff Schlom, et al.. (2010). Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. Clinical Cancer Research. 17(4). 907–917. 201 indexed citations

17.

Nesslinger, Nancy J., Alvin V. Ng, Kwong-Yok Tsang, et al.. (2010). A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients. Clinical Cancer Research. 16(15). 4046–4056. 45 indexed citations

18.

Madan, Ravi A., James L. Gulley, Jeffrey Schlom, et al.. (2008). Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy. Clinical Cancer Research. 14(14). 4526–4531. 119 indexed citations

19.

Dahut, William L., Charity D. Scripture, Edwin M. Posadas, et al.. (2008). A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Clinical Cancer Research. 14(1). 209–214. 142 indexed citations

20.

Gulley, James L., Philip M. Arlen, Kwong-Yok Tsang, et al.. (2008). Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. Clinical Cancer Research. 14(10). 3060–3069. 176 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact